Wilmington, DE – In a landmark decision that underscores the paramount importance of transparency and good faith in corporate governance, the Delaware Court of Chancery has ruled that a director or officer who deliberately withholds material information from the board commits a breach of the duty of loyalty. Furthermore, the court determined that the destruction of corporate documents during a board investigation can, in itself, constitute an independent breach of this fundamental fiduciary duty. The ruling in Sarwal v. NephroSant, Inc., C.A. No. 2023-0222-BWD, issued on November 12, 2026, also decisively holds that a director or officer found to have violated the duty of loyalty forfeits their right to indemnification for the costs incurred by the board in investigating their conduct. This decision, authored by Vice Chancellor David, provides critical guidance for corporate fiduciaries and reinforces Delaware’s commitment to robust director accountability.

The case centers on Dr. Minnie Sarwal, the founder of NephroSant, Inc., a biotechnology firm specializing in diagnostic testing for kidney transplant rejection. The company’s flagship product, QSant, was the subject of a Medicare coverage application initiated in 2020. At the time of this crucial application, NephroSant described QSant as a six-biomarker test. However, a critical alteration occurred while the application was under review by Medicare. Dr. Sarwal, who also served as a director of NephroSant, along with the company’s laboratory directors, made the decision to remove one of the six biomarkers from the test’s algorithm. This modification was reportedly made due to concerns about the biomarker’s potential degradation during shipping.

Crucially, Dr. Sarwal did not disclose this significant change to the NephroSant board of directors. Consequently, subsequent submissions to Medicare continued to represent QSant as a six-biomarker test, creating a material discrepancy between the company’s representations to regulatory bodies and the actual composition of its diagnostic product.

A Year of Silence and Discovery

Approximately a year after the initial Medicare application and the undisclosed modification, NephroSant employees brought the discrepancy to the attention of the board. This revelation triggered a formal response from the board, which promptly established a special committee to conduct a thorough investigation into the matter. The investigation aimed to ascertain the circumstances surrounding the change in the QSant algorithm and the lack of disclosure to the board and Medicare.

As the board-appointed special committee commenced its work, it issued directives for the preservation and production of relevant corporate documents. In a move that would later become a central point of contention, Dr. Sarwal proceeded to delete over 15,000 documents that had been specifically requested as part of the investigation. This extensive deletion occurred after the company had formally directed her to turn over these materials.

Following these events, Dr. Sarwal initiated legal action against NephroSant, seeking indemnification for her expenses incurred in connection with the board’s investigation. NephroSant, in turn, filed a counterclaim, alleging that Dr. Sarwal had breached her fiduciary duties as a director. The ensuing legal battle culminated in a trial before Vice Chancellor David of the Delaware Court of Chancery.

Directors’ Disclosure and Document-Preservation Obligations

The Court’s Interpretation of Fiduciary Duties

In his ruling, Vice Chancellor David meticulously applied the principles established by the Delaware Supreme Court, particularly referencing the seminal 2025 decision in Oracle. The court emphasized that the duty of loyalty, a cornerstone of corporate law, inherently demands good faith and candor. "Good faith requires candor with the board," the court stated, echoing the Supreme Court’s guidance.

The court found that Dr. Sarwal’s failure to inform the board of the material change to the QSant algorithm constituted a breach of her duty of loyalty. The Vice Chancellor rejected the argument that Dr. Sarwal’s personal belief about the necessity of disclosure to Medicare absolved her of responsibility. The court clarified that even if reasonable minds could differ on the specific Medicare disclosure requirements, the alteration presented a "material risk" that the board, not an individual director, was entitled to assess. This highlights the board’s ultimate authority in evaluating and managing risks that could impact the company and its regulatory standing.

Document Destruction as an Independent Breach

Beyond the withholding of information, the court also addressed Dr. Sarwal’s destruction of corporate documents. Vice Chancellor David ruled that Dr. Sarwal was under a clear duty to preserve documents pertinent to the board’s investigation. Her subsequent deletion of over 15,000 documents, described by the court as an effort "to impede an investigation focused on her conduct," was deemed not only sanctionable spoliation of evidence but also an independent breach of the duty of loyalty.

The court clarified that this duty of loyalty, which mandates good faith and the preservation of corporate assets and information, exists independently of any confidentiality agreement Dr. Sarwal may have had with the company. Her actions were not a mere contractual dispute but a violation of her core fiduciary obligations as a director.

Financial Ramifications and Indemnification Forfeiture

The court’s judgment included a significant award of damages in favor of NephroSant. Approximately $8 million in damages were awarded, in addition to costs related to the spoliation of evidence. This financial penalty underscores the serious consequences of breaching fiduciary duties.

Perhaps one of the most impactful aspects of the ruling is the forfeiture of indemnification rights. Delaware law generally permits corporations to indemnify directors and officers for expenses incurred in defending litigation arising from their service. However, this protection is contingent upon the individual acting in good faith and being "successful" in the underlying proceedings.

In Sarwal v. NephroSant, the court found that Dr. Sarwal had neither acted in good faith nor achieved success in the investigation into her conduct. Consequently, she was deemed ineligible for indemnification for the costs associated with defending against the board’s investigation and the company’s counterclaim. This ruling serves as a stark warning that egregious breaches of fiduciary duty can have severe financial repercussions, including the loss of corporate-provided legal protections.

Directors’ Disclosure and Document-Preservation Obligations

Broader Implications for Corporate Governance

The Sarwal v. NephroSant decision carries significant implications for corporate governance, particularly for companies operating under Delaware law. It reinforces several key principles:

  • Candor is Non-Negotiable: The ruling unequivocally states that directors and officers have a fundamental obligation to be candid with their boards. A fiduciary cannot unilaterally decide what information is material or what risks are acceptable. The board, as a collective body, is entrusted with these critical decisions, and it can only fulfill this responsibility if provided with complete and accurate information. This decision emphasizes that the duty of loyalty demands proactive disclosure of material developments, rather than reactive disclosures only when prompted or discovered.

  • Document Destruction as a Serious Breach: The court’s characterization of document destruction as an independent breach of the duty of loyalty, rather than merely a discovery issue, elevates the seriousness of such actions. It signals that deliberate destruction of corporate records intended to thwart an investigation will be treated as a direct violation of fiduciary obligations, carrying both monetary penalties and the potential loss of legal protections. This underscores the importance of robust document retention and destruction policies and the severe consequences of their violation.

  • Indemnification as a Conditional Benefit: The forfeiture of indemnification for Dr. Sarwal highlights that these protections are not automatic. They are earned through good faith conduct and successful defense. This decision will likely prompt companies to more closely scrutinize indemnification claims, especially in cases involving allegations of self-dealing, bad faith, or intentional misconduct. It also serves as a powerful incentive for directors and officers to adhere strictly to their fiduciary duties.

  • Reinforcement of Delaware’s Corporate Law Leadership: This ruling further solidifies Delaware’s reputation as a jurisdiction with a sophisticated and robust framework for corporate law. The court’s clear articulation of fiduciary duties and their consequences provides valuable precedent for future cases and reinforces investor confidence in the integrity of Delaware corporations.

While specific reactions from individuals involved in the case beyond the court’s opinion are not publicly available, the implications of this ruling are likely to be widely discussed within corporate legal and governance circles. Legal experts anticipate that this decision will prompt boards of directors to re-evaluate their oversight mechanisms and communication protocols. Companies may also consider enhancing their internal controls and compliance programs to ensure that all directors and officers are fully aware of their fiduciary obligations and the severe ramifications of failing to uphold them.

In conclusion, the Sarwal v. NephroSant decision serves as a potent reminder that the duty of loyalty is not an abstract concept but a practical mandate for honest and transparent conduct. It underscores that corporate fiduciaries are expected to act with the utmost good faith, prioritizing the interests of the corporation and its stakeholders above their own. The ruling provides a clear and compelling message: the integrity of corporate governance relies on unwavering adherence to these fundamental principles, and breaches will be met with significant legal and financial accountability.

By